Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
Lu
Christine Y
CY
Williams
Kenneth M
KM
March
Lyn
L
Bertouch
James V
JV
Day
Richard O
RO
D000328:Adult; D018501:Antirheumatic Agents / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology*; D001315:Australia; D004363:Drug Utilization; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D018579:Patient Selection; D012217:Rheumatoid Factor / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D012217:Rheumatoid Factor